175 reports of this reaction
1.8% of all ALECTINIB HYDROCHLORIDE reports
#12 most reported adverse reaction
PERIPHERAL SWELLING is the #12 most commonly reported adverse reaction for ALECTINIB HYDROCHLORIDE, manufactured by Genentech, Inc.. There are 175 FDA adverse event reports linking ALECTINIB HYDROCHLORIDE to PERIPHERAL SWELLING. This represents approximately 1.8% of all 9,588 adverse event reports for this drug.
Patients taking ALECTINIB HYDROCHLORIDE who experience peripheral swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PERIPHERAL SWELLING is a less commonly reported adverse event for ALECTINIB HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to peripheral swelling, the following adverse reactions have been reported for ALECTINIB HYDROCHLORIDE:
The following drugs have also been linked to peripheral swelling in FDA adverse event reports:
PERIPHERAL SWELLING has been reported as an adverse event in 175 FDA reports for ALECTINIB HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PERIPHERAL SWELLING accounts for approximately 1.8% of all adverse event reports for ALECTINIB HYDROCHLORIDE, making it a notable side effect.
If you experience peripheral swelling while taking ALECTINIB HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.